====Merck (MRK) reported earnings on Tue 30 Jul 24 (b/o)

 

Merck beats by $0.12, beats on revs; lowers FY24 EPS guidance to reflect negative impact from one-time charge for acquisition of EyeBio, slightly raises rev guidance

• Reports Q2 (Jun) earnings of $2.28 per share, excluding non-recurring items, $0.12 better than the FactSet Consensus of $2.16; revenues rose 7.1% year/year to $16.1 bln vs the $15.87 bln FactSet Consensus.
• KEYTRUDA Sales Grew 16% to $7.3 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 21%.
• Co issues guidance for FY24, sees EPS of $7.94-$8.04, excluding non-recurring items, vs. prior outlook of $8.53 to $8.65. New outlook reflects negative impact from one-time charge of approximately $1.3 bln, or $0.51 per Share, for the acquisition of EyeBio. The FactSet consensus estimate is $8.16; Sees FY24 revs of $63.4-$64.4 bln vs prior guidance of $63.1-$64.3 bln, vs. the $64.29 bln FactSet Consensus.